Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease
K-L Kolho, T Ruuska, E SavilahtiVolume:
96
Year:
2007
Language:
english
Pages:
3
DOI:
10.1111/j.1651-2227.2007.00042.x
File:
PDF, 127 KB
english, 2007